Patents by Inventor Paul Lynes
Paul Lynes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10319981Abstract: A battery balancing system for parallel connected batteries for balancing batteries that are at dissimilar voltages. The system has first and second buses, connected by a current limiter. A high bus takes energy from the highest voltage battery or batteries in the system and transfers the energy through the current limiter to the low bus, which in turn delivers energy to the lowest voltage battery or batteries in the system.Type: GrantFiled: February 23, 2017Date of Patent: June 11, 2019Assignee: Revision Military S.a.r.L.Inventors: Steve Carkner, Eric John Georges Andrasi, Paul Lynes
-
Publication number: 20170244092Abstract: A battery balancing system for parallel connected batteries for balancing batteries that are at dissimilar voltages. The system has first and second buses, connected by a current limiter. A high bus takes energy from the highest voltage battery or batteries in the system and transfers the energy through the current limiter to the low bus, which in turn delivers energy to the lowest voltage battery or batteries in the system.Type: ApplicationFiled: February 23, 2017Publication date: August 24, 2017Applicant: Revision Military S.a.r.L.Inventors: Steve Carkner, Eric John Georges Andrasi, Paul Lynes
-
Patent number: 8835465Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.Type: GrantFiled: November 29, 2012Date of Patent: September 16, 2014Assignee: AstraZeneca ABInventors: Audrey Molina, Michelle Lamb, Paul Lyne, Peter Mohr, Bin Wang, Tao Wang, Dingwei Yu
-
Patent number: 8324252Abstract: This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.Type: GrantFiled: February 1, 2006Date of Patent: December 4, 2012Assignee: Astrazeneca ABInventors: Audrey Davies, Michelle Lamb, Paul Lyne, Tao Wang, Dingwei Yu, Peter Mohr, Bin Wang
-
Publication number: 20100216791Abstract: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.Type: ApplicationFiled: August 15, 2007Publication date: August 26, 2010Applicant: ASTRAZENECAInventors: Brian Aquila, Donald J. Cook, Craig Johnstone, Stephen Lee, Paul Lyne, David Alan Rudge, Melissa Vasbinder, Haixia Wang
-
Publication number: 20100105714Abstract: The invention features compounds of the general Formula (I): (formula should be inserted here) Compounds of Formula (I) possess unexpectedly high affinity for Alk5 and/or Alk4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders.Type: ApplicationFiled: January 30, 2008Publication date: April 29, 2010Applicant: Biogen Idec MA Inc.Inventors: Lihong Sun, Wen-Cherng Lee, Paul Lyne
-
Patent number: 7691865Abstract: Compounds of formula I possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders.Type: GrantFiled: September 5, 2003Date of Patent: April 6, 2010Assignee: Biogen Idec MA Inc.Inventors: Wen-Cherng Lee, Mary Beth Carter, Lihong Sun, Paul Lyne, Claudio Chuaqui, Zhongli Zheng, Juswinder Singh, Paula Boriack-Sjodin
-
Publication number: 20100029643Abstract: The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.Type: ApplicationFiled: November 8, 2007Publication date: February 4, 2010Applicant: ASTRAZENECA ABInventors: Gurmit Grewal, Edward Hennessy, Victor Kamhi, Danyang Li, Paul Lyne, Vibha Oza, Jamal Carlos Saeh, Qibin Su, Bin Yang
-
Publication number: 20090275570Abstract: The invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.Type: ApplicationFiled: April 5, 2006Publication date: November 5, 2009Applicant: ASTRAZENECA ABInventors: Kevin Daly, Nicola Heron, Alexander Hird, Stephanos Ioannidis, James Janetka, Paul Lyne, Jaime Scott, Dorin Toader, Melissa Vasbinder, Dingwei Yu, Yan Yu
-
Publication number: 20090227648Abstract: This invention relates to novel compounds having the formula and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.Type: ApplicationFiled: April 20, 2005Publication date: September 10, 2009Inventors: Paul Lyne, Bin Wang
-
Publication number: 20090170849Abstract: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.Type: ApplicationFiled: April 4, 2007Publication date: July 2, 2009Applicant: ASTRAZENECA ABInventors: Brian Aquila, Paul Lyne, Timothy Pontz
-
Publication number: 20090163525Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.Type: ApplicationFiled: April 4, 2007Publication date: June 25, 2009Applicant: ASTRAZENECA ABInventors: Brian A. Aquila, Paul Lyne, Timothy Pontz
-
Publication number: 20090149484Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.Type: ApplicationFiled: April 17, 2007Publication date: June 11, 2009Applicant: ASTRAZENECA ABInventors: Brian Aquila, Paul Lyne, Timothy Pontz
-
Publication number: 20090118261Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.Type: ApplicationFiled: August 26, 2005Publication date: May 7, 2009Applicant: ASTRAZENECA ABInventors: Brian Aquila, Leslie Dakin, Jayachandran Ezhuthachan, Stephen Lee, Paul Lyne, Timothy Pontz, XiaoLan Zheng
-
Publication number: 20090092601Abstract: Humanized antibodies to LT-?-R and methods of use thereof are provided.Type: ApplicationFiled: June 30, 2008Publication date: April 9, 2009Applicant: Biogen Idec MA Inc.Inventors: Ellen Garber, Paul Lyne, Jose William Saldanha
-
Publication number: 20090054396Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.Type: ApplicationFiled: September 8, 2008Publication date: February 26, 2009Applicant: ASTRAZENECA ABInventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Mei Su, Dingwei Yu, Stephanie Springer
-
Publication number: 20090054469Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.Type: ApplicationFiled: August 28, 2005Publication date: February 26, 2009Applicant: ASTRAZENECA ABInventors: Brian Aquila, Paul Lyne, Timothy Pontz
-
Publication number: 20080312206Abstract: The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula which possess CSF 1R kinase inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.Type: ApplicationFiled: December 19, 2006Publication date: December 18, 2008Applicant: AstraZeneca ABInventors: Brian Aquila, Donald Cook, Leslie Dakin, Stephanos Ioannidis, Paul Lyne, David Scott, Xiaolan Zheng
-
Publication number: 20080306096Abstract: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.Type: ApplicationFiled: December 19, 2006Publication date: December 11, 2008Applicant: ASTRAZENECA ABInventors: Brian Aquila, Jayachandran Ezhuthachan, Paul Lyne, Timothy Pontz, Xiaolan Zheng
-
Publication number: 20080275022Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.Type: ApplicationFiled: June 14, 2005Publication date: November 6, 2008Applicant: AstraZeneca ABInventors: Brian Aquila, Les Dakin, Jayachandran Ezhuthachan, John Lee, Paul Lyne, Timothy Pontz